Latest ALK inhibitor Stories
TUCSON, Ariz., Jan. 21, 2015 /PRNewswire/ -- Ventana Medical Systems, Inc.
-- CHOP and Penn Medicine Experts Define Riskier Mutations in Neuroblastoma, Setting Stage for Clinical Trial-- PHILADELPHIA, Nov.
LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
- Ceritinib achieved overall response rate of 58.5%, with a median progression-free survival of 8.2 months1 EAST HANOVER, N.J., June 2, 2014 /PRNewswire/ -- Novartis today announced data showing
Ceritinib (brand name Zykadia(TM)) will be used for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or
- Zykadia (ceritinib) demonstrated an overall response rate of 54.6% in patients with ALK+ metastatic NSCLC who have no other treatment option EAST HANOVER, N.J., April 29, 2014 /PRNewswire/
- Data showed investigational treatment LDK378 (ceritinib) also achieved a median progression-free survival of seven months EAST HANOVER, N.J., March 26, 2014 /PRNewswire/ -- Novartis today
The findings of a recent study indicate that routine testing with both fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) may enhance the detection of ALK-positive non-small cell lung cancer (NSCLC).
PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene.
- A political dynamiter.